Envista obtains fda clearance for assisted intelligence mandibular nerve tracing

Brea, calif. , march 28, 2022 /prnewswire/ -- envista holdings corporation (nyse: nvst) ("envista") -- envista announced today the 510(k) food and drug administration (fda) clearance of its assisted intelligence (ai) mandibular nerve tracing feature in its image acquisition and diagnostic software platform dtx studio clinic.
NVST Ratings Summary
NVST Quant Ranking